Literature DB >> 27590090

Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control.

John W McEvoy1, Yuan Chen2, Andreea Rawlings2, Ron C Hoogeveen3, Christie M Ballantyne3, Roger S Blumenthal4, Josef Coresh2, Elizabeth Selvin2.   

Abstract

BACKGROUND: The optimal systolic blood pressure (SBP) treatment goal is in question, with SPRINT (Systolic Blood Pressure Intervention Trial) suggesting benefit for 120 mm Hg. However, achieving an SBP this low may reduce diastolic blood pressure (DBP) to levels that could compromise myocardial perfusion.
OBJECTIVES: This study sought to examine the independent association of DBP with myocardial damage (using high-sensitivity cardiac troponin-T [hs-cTnT]) and with coronary heart disease (CHD), stroke, or death over 21 years.
METHODS: The authors studied 11,565 adults from the ARIC (Atherosclerosis Risk In Communities) cohort, analyzing DBP and hs-cTnT associations as well as prospective associations between DBP and events.
RESULTS: Mean baseline age was 57 years, 57% of patients were female, and 25% were black. Compared with persons who had DBP between 80 to 89 mm Hg at baseline (ARIC visit 2), the adjusted odds ratio of having hs-cTnT ≥14 ng/l at that visit was 2.2 and 1.5 in those with DBP <60 mm Hg and 60 to 69 mm Hg, respectively. Low DBP at baseline was also independently associated with progressive myocardial damage on the basis of estimated annual change in hs-cTnT over the 6 years between ARIC visits 2 and 4. In addition, compared with a DBP of 80 to 89 mm Hg, a DBP <60 mm Hg was associated with incident CHD and mortality, but not with stroke. The DBP and incident CHD association was strongest with baseline hs-cTnT ≥14 ng/l (p value for interaction <0.001). Associations of low DBP with prevalent hs-cTnT and incident CHD were most pronounced among patients with baseline SBP ≥120 mm Hg.
CONCLUSIONS: Particularly among adults with an SBP ≥120 mm Hg, and thus elevated pulse pressure, low DBP was associated with subclinical myocardial damage and CHD events. When titrating treatment to SBP <140 mm Hg, it may be prudent to ensure that DBP levels do not fall below 70 mm Hg, and particularly not below 60 mm Hg.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  J-curve; coronary heart disease; coronary perfusion; high-sensitivity troponin; hypertension

Mesh:

Substances:

Year:  2016        PMID: 27590090      PMCID: PMC5089057          DOI: 10.1016/j.jacc.2016.07.754

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  A British Medical Association Lecture on THE SIGNIFICANCE OF A RAISED BLOOD PRESSURE.

Authors:  J Hay
Journal:  Br Med J       Date:  1931-07-11

2.  Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.

Authors:  Christopher R deFilippi; James A de Lemos; Robert H Christenson; John S Gottdiener; Willem J Kop; Min Zhan; Stephen L Seliger
Journal:  JAMA       Date:  2010-11-15       Impact factor: 56.272

3.  High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men.

Authors:  Kai M Eggers; Jinan Al-Shakarchi; Lars Berglund; Bertil Lindahl; Agneta Siegbahn; Lars Wallentin; Björn Zethelius
Journal:  Am Heart J       Date:  2013-08-13       Impact factor: 4.749

4.  Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; T Gordon; M J Schwartz
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

5.  Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort.

Authors:  W D Rosamond; A R Folsom; L E Chambless; C H Wang; P G McGovern; G Howard; L S Copper; E Shahar
Journal:  Stroke       Date:  1999-04       Impact factor: 7.914

6.  Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study.

Authors:  Justin T Saunders; Vijay Nambi; James A de Lemos; Lloyd E Chambless; Salim S Virani; Eric Boerwinkle; Ron C Hoogeveen; Xiaoxi Liu; Brad C Astor; Thomas H Mosley; Aaron R Folsom; Gerardo Heiss; Josef Coresh; Christie M Ballantyne
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

7.  Comparison of blood pressure measurements between an automated oscillometric device and a Hawksley random-zero sphygmomanometer in the northern Sweden MONICA study.

Authors:  Marie Eriksson; Bo Carlberg; Jan-Håkan Jansson
Journal:  Blood Press Monit       Date:  2012-08       Impact factor: 1.444

8.  Constructing inverse probability weights for marginal structural models.

Authors:  Stephen R Cole; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

9.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?

Authors:  L Farnett; C D Mulrow; W D Linn; C R Lucey; M R Tuley
Journal:  JAMA       Date:  1991 Jan 23-30       Impact factor: 56.272

10.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

View more
  89 in total

1.  Impact of a Population Health Management Intervention on Disparities in Cardiovascular Disease Control.

Authors:  Aisha James; Seth A Berkowitz; Jeffrey M Ashburner; Yuchiao Chang; Daniel M Horn; Sandra M O'Keefe; Steven J Atlas
Journal:  J Gen Intern Med       Date:  2018-01-08       Impact factor: 5.128

Review 2.  Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population.

Authors:  Kamal Shemisa; Anish Bhatt; Daniel Cheeran; Ian J Neeland
Journal:  Curr Heart Fail Rep       Date:  2017-08

Review 3.  The J-shaped Curve for Blood Pressure and Cardiovascular Disease Risk: Historical Context and Recent Updates.

Authors:  Faisal Rahman; John W McEvoy
Journal:  Curr Atheroscler Rep       Date:  2017-08       Impact factor: 5.113

Review 4.  Dangers of Overly Aggressive Blood Pressure Control.

Authors:  Faisal Rahman; John W McEvoy
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

5.  Prognostic value of daytime heart rate, blood pressure, their products and quotients in chronic heart failure.

Authors:  Anna Kowalczys; Michał Bohdan; Marcin Gruchała
Journal:  Cardiol J       Date:  2017-11-13       Impact factor: 2.737

6.  Blood Pressure and Memory: Novel Approaches to Modeling Nonlinear Effects in Longitudinal Studies.

Authors:  Anran Liu; Zhaowen Sun; Eric M McDade; Tiffany F Hughes; Mary Ganguli; Chung-Chou H Chang
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Oct-Dec       Impact factor: 2.703

Review 7.  Thus Far and No Further: Should Diastolic Hypotension Limit Intensive Blood Pressure Lowering?

Authors:  Marcel Ruzicka; Cedric Edwards; Brendan McCormick; Swapnil Hiremath
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-09-14

8.  Post-stroke diastolic blood pressure and risk of recurrent vascular events.

Authors:  J-H Park; B Ovbiagele
Journal:  Eur J Neurol       Date:  2017-09-22       Impact factor: 6.089

9.  Relation of Diastolic Blood Pressure and Coronary Artery Calcium to Coronary Events and Outcomes (From the Multi-Ethnic Study of Atherosclerosis).

Authors:  Faisal Rahman; Mahmoud Al Rifai; Michael J Blaha; Khurram Nasir; Matthew J Budoff; Bruce M Psaty; Wendy S Post; Roger S Blumenthal; John W McEvoy
Journal:  Am J Cardiol       Date:  2017-08-08       Impact factor: 2.778

10.  Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.

Authors:  Brian A Bergmark; Benjamin M Scirica; Ph Gabriel Steg; Christina L Fanola; Yared Gurmu; Ofri Mosenzon; Avivit Cahn; Itamar Raz; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2018-06-21       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.